CERVICAL CANCER About Gynecologic Cancer

Total Page:16

File Type:pdf, Size:1020Kb

CERVICAL CANCER About Gynecologic Cancer CERVICAL CANCER About Gynecologic Cancer There are five main types of cancer that affect a woman’s reproductive organs: cervical, ovarian, uterine, vaginal, and vulvar. As a group, they are referred to as gynecologic (GY-neh-kuh-LAH-jik) cancer. (A sixth type of gynecologic cancer is the very rare fallopian tube cancer.) This fact sheet about cervical cancer is part of the Centers for Disease Control and Prevention’s (CDC) Inside Knowledge: About Gynecologic Cancer campaign. The campaign helps women get the facts about gynecologic cancer, providing important “inside knowledge” about their bodies and health. What is cervical cancer? Cancer is a disease in which cells Are there tests that can prevent cervical cancer or find it early? in the body grow out of control. There are two tests that can either help prevent cervical cancer or find it early: Cancer is always named for the part of the body where it starts, even if it • Depending on your age, your doctor may recommend you have a Pap spreads to other body parts later. test, or an HPV test, or both tests together. When cancer starts in the • The Pap test (or Pap smear) looks for precancers, cell changes, on the cervix, it is called cervical cancer. cervix that can be treated, so that cervical cancer is prevented. The Pap The cervix is the lower, narrow test also can find cervical cancer early, when treatment is most effective. end of the uterus. The cervix The Pap test only screens for cervical cancer. It does not screen for any connects the vagina (the birth canal) other gynecologic cancer. to the upper part of the uterus. The • The HPV test looks for HPV—the virus that can cause precancerous uterus (or womb) is where a baby cell changes and cervical cancer. grows when a woman is pregnant. Cervical cancer is the easiest gynecologic cancer to prevent with regular screening tests and Who gets cervical cancer? cancer. HPV is a common virus that is passed from one person to follow-up. It also is highly curable All women are at risk for cervical another during sex. Most sexually when found and treated early. cancer. It occurs most often in active people will have HPV at women over age 30. Each year, some point in their lives, but few approximately 12,000 women in the women will get cervical cancer. United States get cervical cancer. The human papillomavirus (HPV) What are the symptoms? is the main cause of cervical Early on, cervical cancer may not cause signs and symptoms. Advanced cervical cancer may Fallopian Tube cause bleeding or discharge from Ovary the vagina that is not normal for you, Uterus such as bleeding after sex. If you have Cervix any of these signs, see your doctor. Vagina They may be caused by something Vulva other than cancer, but the only way to know is to see your doctor. cdc.gov/cancer/knowledge 800-CDC-INFO What raises a woman’s chance women who are vaccinated of getting cervical cancer? against HPV need to have When should I get tested regular Pap tests to screen for Almost all cervical cancers are for cervical cancer? cervical cancer. To learn more caused by HPV. You are more about the HPV vaccine visit likely to get HPV if you started The Pap test is one of the most www.cdc.gov/hpv. reliable and effective cancer having sex at an early age, or if • Don’t smoke. screening tests available. The you or your partner have had sex Pap test is recommended for all with several others. However, any • Use condoms during sex.* woman who has ever had sex is at women between the ages of 21 • Limit your number of sexual risk for HPV. and 29 years old. If your Pap test partners. results are normal, your doctor There are many types of HPV. * HPV infection can occur in both male and may say that you will not need Usually HPV will go away on its female genital areas that are covered or another Pap test for three years. own, but if it does not, it may protected by a latex condom, as well as in cause cervical cancer over time. areas that are not covered. While the effect If you are 30 years old or older, of condoms in preventing HPV infection is In addition to having HPV, these unknown, condom use has been associated you may choose to have a Pap with a lower rate of cervical cancer. test, or an HPV test, or both tests things also can increase your risk together. If the results are normal, of cervical cancer: your chance of getting cervical • Smoking. What should I do if my doctor says I have cervical cancer? cancer in the next few years is • Having HIV (the virus that very low. Your doctor may then causes AIDS) or another If your doctor says that you have say that you can wait up to five condition that makes it hard for cervical cancer, ask to be referred years for your next screening. your body to fight off health to a gynecologic oncologist—a The HPV test is also used to problems. doctor who has been trained to treat cancers like this. This doctor provide more information when • Using birth control pills for a will work with you to create a women aged 21 years or older long time (five or more years). treatment plan. have unclear Pap test results. • Having given birth to three or For women aged 21-65, it is more children. Where can I find free or important to continue getting a low-cost cervical cancer Pap and/or HPV test as directed How can I prevent cervical screening tests? by your doctor—even if you think cancer? you are too old to have a child If you have a low income or do not • See your doctor regularly for or are not having sex anymore. have insurance, you may be able a Pap and/or HPV test. However, your doctor may tell you to get a free or low-cost cervical that you do not need to have a • Follow up with your doctor if cancer screening test through the Pap or HPV test if either of these your cervical cancer screening National Breast and Cervical Cancer Early Detection Program. To learn is true for you: test results are not normal. more, call 800-CDC-INFO or visit • Get the HPV vaccine. It protects • You are older than 65 and have www.cdc.gov/cancer/nbccedp. against the types of HPV that had a normal Pap or HPV test most often cause cervical, for several years. vaginal, and vulvar cancers. It Where can I find more • You have had your cervix is recommended for preteens removed as part of a (both boys and girls) aged 11 information about cervical and total hysterectomy for to 12 years, but can be given other gynecologic cancers? non-cancerous conditions, as early as age 9 and until age Centers for Disease Control and like fibroids. 26. The vaccine is given in a Prevention: 800-CDC-INFO or series of either two or three www.cdc.gov/cancer/gynecologic shots, depending on age. It is National Cancer Institute: important to note that even 800-4-CANCER or www.cancer.gov cdc.gov/cancer/knowledge 800-CDC-INFO About Gynecologic Cancer CDC Publication #99-9123, Revised January 2019.
Recommended publications
  • Reference Sheet 1
    MALE SEXUAL SYSTEM 8 7 8 OJ 7 .£l"00\.....• ;:; ::>0\~ <Il '"~IQ)I"->. ~cru::>s ~ 6 5 bladder penis prostate gland 4 scrotum seminal vesicle testicle urethra vas deferens FEMALE SEXUAL SYSTEM 2 1 8 " \ 5 ... - ... j 4 labia \ ""\ bladderFallopian"k. "'"f"";".'''¥'&.tube\'WIT / I cervixt r r' \ \ clitorisurethrauterus 7 \ ~~ ;~f4f~ ~:iJ 3 ovaryvagina / ~ 2 / \ \\"- 9 6 adapted from F.L.A.S.H. Reproductive System Reference Sheet 3: GLOSSARY Anus – The opening in the buttocks from which bowel movements come when a person goes to the bathroom. It is part of the digestive system; it gets rid of body wastes. Buttocks – The medical word for a person’s “bottom” or “rear end.” Cervix – The opening of the uterus into the vagina. Circumcision – An operation to remove the foreskin from the penis. Cowper’s Glands – Glands on either side of the urethra that make a discharge which lines the urethra when a man gets an erection, making it less acid-like to protect the sperm. Clitoris – The part of the female genitals that’s full of nerves and becomes erect. It has a glans and a shaft like the penis, but only its glans is on the out side of the body, and it’s much smaller. Discharge – Liquid. Urine and semen are kinds of discharge, but the word is usually used to describe either the normal wetness of the vagina or the abnormal wetness that may come from an infection in the penis or vagina. Duct – Tube, the fallopian tubes may be called oviducts, because they are the path for an ovum.
    [Show full text]
  • Ovarian Cancer and Cervical Cancer
    What Every Woman Should Know About Gynecologic Cancer R. Kevin Reynolds, MD The George W. Morley Professor & Chief, Division of Gyn Oncology University of Michigan Ann Arbor, MI What is gynecologic cancer? Cancer is a disease where cells grow and spread without control. Gynecologic cancers begin in the female reproductive organs. The most common gynecologic cancers are endometrial cancer, ovarian cancer and cervical cancer. Less common gynecologic cancers involve vulva, Fallopian tube, uterine wall (sarcoma), vagina, and placenta (pregnancy tissue: molar pregnancy). Ovary Uterus Endometrium Cervix Vagina Vulva What causes endometrial cancer? Endometrial cancer is the most common gynecologic cancer: one out of every 40 women will develop endometrial cancer. It is caused by too much estrogen, a hormone normally present in women. The most common cause of the excess estrogen is being overweight: fat cells actually produce estrogen. Another cause of excess estrogen is medication such as tamoxifen (often prescribed for breast cancer treatment) or some forms of prescribed estrogen hormone therapy (unopposed estrogen). How is endometrial cancer detected? Almost all endometrial cancer is detected when a woman notices vaginal bleeding after her menopause or irregular bleeding before her menopause. If bleeding occurs, a woman should contact her doctor so that appropriate testing can be performed. This usually includes an endometrial biopsy, a brief, slightly crampy test, performed in the office. Fortunately, most endometrial cancers are detected before spread to other parts of the body occurs Is endometrial cancer treatable? Yes! Most women with endometrial cancer will undergo surgery including hysterectomy (removal of the uterus) in addition to removal of ovaries and lymph nodes.
    [Show full text]
  • Echography of the Cervix and Uterus During the Proliferative and Secretory Phases of the Menstrual Cycle in Bonnet Monkeys (Macaca Radiata)
    Journal of the American Association for Laboratory Animal Science Vol 53, No 1 Copyright 2014 January 2014 by the American Association for Laboratory Animal Science Pages 18–23 Echography of the Cervix and Uterus during the Proliferative and Secretory Phases of the Menstrual Cycle in Bonnet Monkeys (Macaca radiata) Uddhav K Chaudhari,1,* Siddnath M Metkari,2 Dhyananjay D Manjaramkar,2 Geetanjali Sachdeva,1 Rajendra Katkam,1 Atmaram H Bandivdekar,3 Abhishek Mahajan,4 Meenakshi H Thakur,4 and Sanjiv D Kholkute1 We undertook the present study to investigate the echographic characteristics of the uterus and cervix of female bonnet monkeys (Macaca radiata) during the proliferative and secretory phases of the menstrual cycle. The cervix was tortuous in shape and measured 2.74 ± 0.30 cm (mean ± SD) in width by 3.10 ± 0.32 cm in length. The cervical lumen contained 2 or 3 col- liculi, which projected from the cervical canal. The echogenicity of cervix varied during proliferative and secretory phases. The uterus was pyriform in shape (2.46 ± 0.28 cm × 1.45 ± 0.19 cm) and consisted of serosa, myometrium, and endometrium. The endometrium generated a triple-line pattern; the outer and central lines were hyperechogenic, whereas the inner line was hypoechogenic. The endometrium was significantly thicker during the secretory phase (0.69 ± 0.12 cm) than during the proliferative phase (0.43 ± 0.15 cm). Knowledge of the echogenic changes in the female reproductive organs of bonnet monkeys during a regular menstrual cycle may facilitate understanding of other physiologic and pathophysiologic changes. Ultrasound imaging is a noninvasive, atraumatic, and simple Materials and Methods method to assess various organs in humans and nonhuman pri- Animals and husbandry practices.
    [Show full text]
  • Primary Immature Teratoma of the Thigh Fig
    CORRESPONDENCE 755 8. Gray W, Kocjan G. Diagnostic Cytopathology. 2nd ed. London: Delete all that do not apply: Elsevier Health Sciences, 2003; 677. 9. Richards A, Dalrymple C. Abnormal cervicovaginal cytology, unsatis- Cervix, colposcopic biopsy/LLETZ/cone biopsy: factory colposcopy and the use of vaginal estrogen cream: an obser- vational study of clinical outcomes for women in low estrogen states. Diagnosis: NIL (No intraepithelial lesion WHO 2014) J Obstet Gynaecol Res 2015; 41: 440e4. LSIL (CIN 1 with HPV effect WHO 2014) 10. Darragh TM, Colgan TJ, Cox T, et al. The lower anogenital squamous HSIL (CIN2/3 WHO 2014) terminology standardization project for HPV-associated lesions: back- Squamous cell carcinoma ground and consensus recommendation from the College of American Immature squamous metaplasia Pathologists and the American Society for Colposcopy and Cervical Adenocarcinoma in situ (AIS, HGGA) e Adenocarcinoma Pathology. Arch Pathol Lab Med 2012; 136: 1267 97. Atrophic change 11. McCluggage WG. Endocervical glandular lesions: controversial aspects e Extending into crypts: Not / Idenfied and ancillary techniques. J Clin Pathol 2013; 56: 164 73. Epithelial stripping: Not / Present 12. World Health Organization (WHO). Comprehensive Cervical Cancer Invasive disease: Not / Idenfied / Micro-invasive Control: A Guide to Essential Practice. 2nd ed. Geneva: WHO, 2014. Depth of invasion: mm Transformaon zone: Not / Represented Margins: DOI: https://doi.org/10.1016/j.pathol.2019.07.014 Ectocervical: Not / Clear Endocervical: Not / Clear Circumferenal: Not / Clear p16 status: Negave / Posive Primary immature teratoma of the thigh Fig. 3 A proposed synoptic reporting format for pathologists reporting colposcopic biopsies and cone biopsies or LLETZ. Sir, Teratomas are germ cell tumours composed of a variety of HSIL, AIS, micro-invasive or more advanced invasive dis- somatic tissues derived from more than one germ layer 12 ease.
    [Show full text]
  • Squamous Cell Carcinoma Arising in an Ovarian Mature Cystic Teratoma
    Case Report Obstet Gynecol Sci 2013;56(2):121-125 http://dx.doi.org/10.5468/OGS.2013.56.2.121 pISSN 2287-8572 · eISSN 2287-8580 Squamous cell carcinoma arising in an ovarian mature cystic teratoma complicating pregnancy Nae-Ri Yun1, Jung-Woo Park1, Min-Kyung Hyun1, Jee-Hyun Park1, Suk-Jin Choi2, Eunseop Song1 Departments of 1Obstetrics and Gynecology and 2Pathology, Inha University College of Medicine, Incheon, Korea Mature cystic teratomas of the ovary (MCT) are usually observed in women of reproductive age with the most dreadful complication being malignant transformation which occurs in approximately 1% to 3% of MCTs. In this case report, we present a patient with squamous cell carcinoma which developed from a MCT during pregnancy. The patient was treated conservatively without adjuvant chemotherapy and was followed without evidence of disease for more than 60 months using conventional tools as well as positron emission tomography-computed tomography following the initial surgery. We report this case along with the review of literature. Keywords: Dermoid cyst; Malignant transformation; Observation; Positron emission tomography-computed tomography Introduction An 18 cm solid and cystic left ovarian mass with a smooth surface and two small right ovarian cysts were detected re- The incidence of adnexal masses during pregnancy is 1% to sulting in a laparotomy at 13 weeks of gestation and left sal- 9% [1]. Mature cystic teratomas (MCT) are common during pingo-oophorectomy and right ovarian cystectomy (Fig. 1C). pregnancy with the most dreadful complication being ma- The report of the frozen section from both tissues revealed lignant transformation which occurs in approximately 1% to MCT.
    [Show full text]
  • Pembrolizumab in Vaginal and Vulvar Squamous Cell Carcinoma: a Case Series from a Phase II Basket Trial Jefrey A
    www.nature.com/scientificreports OPEN Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial Jefrey A. How 1, Amir A. Jazaeri 1, Pamela T. Soliman1, Nicole D. Fleming1, Jing Gong2, Sarina A. Piha‑Paul2, Filip Janku 2, Bettzy Stephen 2 & Aung Naing 2* Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single‑agent pembrolizumab as part of a phase II basket clinical trial to evaluate efcacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had signifcant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confrmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD‑L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD‑L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical beneft to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efcacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.
    [Show full text]
  • Influence of Age on Histologic Outcome of Cervical Intraepithelial Neoplasia
    www.nature.com/scientificreports OPEN Infuence of age on histologic outcome of cervical intraepithelial neoplasia during observational Received: 10 May 2017 Accepted: 6 April 2018 management: results from large Published: xx xx xxxx cohort, systematic review, meta- analysis Christine Bekos1, Richard Schwameis1, Georg Heinze2, Marina Gärner1, Christoph Grimm1, Elmar Joura1,4, Reinhard Horvat3, Stephan Polterauer1,4 & Mariella Polterauer1 Aim of this study was to investigate the histologic outcome of cervical intraepithelial neoplasia (CIN) during observational management. Consecutive women with histologically verifed CIN and observational management were included. Histologic fndings of initial and follow-up visits were collected and persistence, progression and regression rates at end of observational period were assessed. Uni- and multivariate analyses were performed. A systematic review of the literature and meta-analysis was performed. In 783 women CIN I, II, and III was diagnosed by colposcopically guided biopsy in 42.5%, 26.6% and 30.9%, respectively. Younger patients had higher rates of regression (p < 0.001) and complete remission (< 0.001) and lower rates of progression (p = 0.003). Among women aged < 25, 25 < 30, 30 < 35, 35 < 40 years, and > 40 years, regression rates were 44.7%, 33.7%, 30.9%, 27.3%, and 24.9%, respectively. Pooled analysis of published data showed similar results. Multivariable analysis showed that with each fve years of age, the odds for regression reduced by 21% (p < 0.001) independently of CIN grade (p < 0.001), and presence of HPV high-risk infection (p < 0.001). Patient’s age has a considerable infuence on the natural history of CIN – independent of CIN grade and HPV high- risk infection.
    [Show full text]
  • Clinical Radiation Oncology Review
    Clinical Radiation Oncology Review Daniel M. Trifiletti University of Virginia Disclaimer: The following is meant to serve as a brief review of information in preparation for board examinations in Radiation Oncology and allow for an open-access, printable, updatable resource for trainees. Recommendations are briefly summarized, vary by institution, and there may be errors. NCCN guidelines are taken from 2014 and may be out-dated. This should be taken into consideration when reading. 1 Table of Contents 1) Pediatrics 6) Gastrointestinal a) Rhabdomyosarcoma a) Esophageal Cancer b) Ewings Sarcoma b) Gastric Cancer c) Wilms Tumor c) Pancreatic Cancer d) Neuroblastoma d) Hepatocellular Carcinoma e) Retinoblastoma e) Colorectal cancer f) Medulloblastoma f) Anal Cancer g) Epndymoma h) Germ cell, Non-Germ cell tumors, Pineal tumors 7) Genitourinary i) Craniopharyngioma a) Prostate Cancer j) Brainstem Glioma i) Low Risk Prostate Cancer & Brachytherapy ii) Intermediate/High Risk Prostate Cancer 2) Central Nervous System iii) Adjuvant/Salvage & Metastatic Prostate Cancer a) Low Grade Glioma b) Bladder Cancer b) High Grade Glioma c) Renal Cell Cancer c) Primary CNS lymphoma d) Urethral Cancer d) Meningioma e) Testicular Cancer e) Pituitary Tumor f) Penile Cancer 3) Head and Neck 8) Gynecologic a) Ocular Melanoma a) Cervical Cancer b) Nasopharyngeal Cancer b) Endometrial Cancer c) Paranasal Sinus Cancer c) Uterine Sarcoma d) Oral Cavity Cancer d) Vulvar Cancer e) Oropharyngeal Cancer e) Vaginal Cancer f) Salivary Gland Cancer f) Ovarian Cancer & Fallopian
    [Show full text]
  • WHO Guidelines for Treatment of Cervical Intraepithelial Neoplasia 2–3 and Adenocarcinoma in Situ
    WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ Cryotherapy Large loop excision of the transformation zone Cold knife conization WHO guidelines WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization Catalogage à la source : Bibliothèque de l’OMS WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization. 1.Cervical Intraepithelial Neoplasia – diagnosis. 2.Cervical Intraepithelial Neoplasia – therapy. 3.Cervical Intraepithelial Neoplasia – surgery. 4.Adenocarcinoma – diagnosis. 5.Adenocarcinoma – therapy. 6.Cryotherapy – utilization. 7.Conization – methods. 8.Uterine Cervical Neoplasms – prevention and control. 9.Guideline. I.World Health Organization. ISBN 978 92 4 150677 9 (Classification NLM : WP 480) © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Caring for Yourself After Your Cone Biopsy of the Cervix | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Caring for Yourself After Your Cone Biopsy of the Cervix This information explains how to care for yourself after a cone biopsy of your cervix. About Your Cone Biopsy of the Cervix Your cervix is the bottom part of your uterus. It connects your uterus to your vagina (see Figure 1). It’s the part of your uterus that dilates (opens) during childbirth. When you have your period, menstrual blood flows through your cervix to your vagina and out of your body. Figure 1. Uterus, cervix, and vagina Caring for Yourself After Your Cone Biopsy of the Cervix 1/3 During a cone biopsy, your doctor will remove a small, cone-shaped part of your cervix. They will study it under a microscope to look for abnormal cells. It usually takes about 4 to 6 weeks for your cervix to heal after this procedure. Caring for Yourself at Home In the first 24 hours after your procedure: Drink 8 to 12 (8-ounce) glasses of liquids. Eat well-balanced, healthy meals. The first 4 days after your procedure, you may have vaginal discharge that looks like menstrual bleeding. The amount varies for everyone. Over the next 2 to 3 weeks after your procedure, your vaginal discharge will become clear and watery and then will stop. Use sanitary pads for vaginal discharge. For 4 to 6 weeks after your procedure or until your doctor tells you your cervix is healed: Don’t put anything inside your vagina (such as tampons and douches) or have vaginal intercourse. Take showers instead of baths.
    [Show full text]
  • Colposcopy of the Uterine Cervix
    THE CERVIX: Colposcopy of the Uterine Cervix • I. Introduction • V. Invasive Cancer of the Cervix • II. Anatomy of the Uterine Cervix • VI. Colposcopy • III. Histology of the Normal Cervix • VII: Cervical Cancer Screening and Colposcopy During Pregnancy • IV. Premalignant Lesions of the Cervix The material that follows was developed by the 2002-04 ASCCP Section on the Cervix for use by physicians and healthcare providers. Special thanks to Section members: Edward J. Mayeaux, Jr, MD, Co-Chair Claudia Werner, MD, Co-Chair Raheela Ashfaq, MD Deborah Bartholomew, MD Lisa Flowers, MD Francisco Garcia, MD, MPH Luis Padilla, MD Diane Solomon, MD Dennis O'Connor, MD Please use this material freely. This material is an educational resource and as such does not define a standard of care, nor is intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate. I. AN INTRODUCTION TO THE NORMAL CERVIX, NEOPLASIA, AND COLPOSCOPY The uterine cervix presents a unique opportunity to clinicians in that it is physically and visually accessible for evaluation. It demonstrates a well-described spectrum of histological and colposcopic findings from health to premalignancy to invasive cancer. Since nearly all cervical neoplasia occurs in the presence of human papillomavirus infection, the cervix provides the best-defined model of virus-mediated carcinogenesis in humans to date.
    [Show full text]
  • Vaginal Cancer, Risk Factors, and Prevention Risk Factors for Vaginal
    cancer.org | 1.800.227.2345 Vaginal Cancer, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for vaginal cancer. ● Risk Factors for Vaginal Cancer ● What Causes Vaginal Cancer? Prevention There's no way to completely prevent cancer. But there are things you can do that might help lower your risk. Learn more here. ● Can Vaginal Cancer Be Prevented? Risk Factors for Vaginal Cancer A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a risk factor, or even many, does not mean that you will get the disease. And 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 some people who get the disease may not have any known risk factors. Scientists have found that certain risk factors make a woman more likely to develop vaginal cancer. But many women with vaginal cancer don’t have any clear risk factors. And even if a woman with vaginal cancer has one or more risk factors, it’s impossible to know for sure how much that risk factor contributed to causing the cancer. Age Squamous cell cancer of the vagina occurs mainly in older women. It can happen at any age, but few cases are found in women younger than 40. Almost half of cases occur in women who are 70 years old or older.
    [Show full text]